| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Department of Bone Biology and Osteoporosis Research, Merck Research Laboratories, West Point, Pennsylvania 19486
Address all correspondence and requests for reprints to: Le T. Duong, Ph.D., Department of Bone Biology and Osteoporosis Research, Merck Research Laboratories, West Point, Pennsylvania 19486.
The vitronectin receptor
vß3 is highly
expressed in osteoclasts and was shown to play a critical role in
osteoclast function in vivo. The objective of this study
was to examine the role of
vß3 integrin in
osteoclast formation in vitro using the inhibitory
disintegrin echistatin, an RGD-containing snake venom. We documented by
immunocytochemistry and Northern blot analysis that during murine
osteoclast-like cell (OCL) formation in a coculture of mouse
osteoblastic MB1.8 cells and bone marrow cells there is increased
expression of the
v and ß3 integrin
subunits. Echistatin binds preferentially to the membrane fraction of
isolated enriched OCLs (IC50 = 0.6 nM), and
this binding is inhibited by vitronectin receptor-blocking polyclonal
antibodies. Additionally, cross-linking of radiolabeled echistatin to
OCLs, followed by immunoprecipitation with antibodies to vitronectin or
fibronectin receptors, shows that
vß3
integrin is the predominant receptor for echistatin in this system. In
this coculture, echistatin completely inhibits the formation of
multinucleated OCLs, but not that of mononuclear prefusion OCLs (pOCs).
This inhibition is RGD and dose dependent (IC50 = 0.7
nM). We tested the hypothesis that inhibition of OCL
formation may be due to interference with pOC migration and found that
echistatin inhibited macrophage colony-stimulating factor-induced
migration and fusion of pOCs (IC50 = 1 and 0.6
nM, respectively). Echistatin inhibition of pOCs migration
and fusion is also RGD dependent. These results suggest that the
integrin
vß3 plays a role in pOC
migration, which can explain the inhibitory effect of echistatin on
multinucleated osteoclast formation in vitro.
This article has been cited by other articles:
![]() |
S. Koga, K. Yogo, K. Yoshikawa, H. Samori, M. Goto, T. Uchida, N. Ishida, and T. Takeya Physical and Functional Association of c-Src and Adhesion and Degranulation Promoting Adaptor Protein (ADAP) in Osteoclastogenesis in Vitro J. Biol. Chem., September 9, 2005; 280(36): 31564 - 31571. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Sato, N. Yamamoto, H. Yamazaki, S. Hashimoto, M. Hino, F. Sakai, and A. Fujie Prevention of the Cryptic Epitope SLAYGLR within Osteopontin Does Not Influence Susceptibility to Candida albicans Infection Antimicrob. Agents Chemother., July 1, 2005; 49(7): 3053 - 3055. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Miyamoto, F. Arai, O. Ohneda, K. Takagi, D. M. Anderson, and T. Suda An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor kappa B ligand Blood, December 15, 2000; 96(13): 4335 - 4343. [Abstract] [Full Text] [PDF] |
||||
![]() |
I Nakamura, M. Pilkington, P. Lakkakorpi, L Lipfert, S. Sims, S. Dixon, G. Rodan, and L. Duong Role of alpha(v)beta(3) integrin in osteoclast migration and formation of the sealing zone J. Cell Sci., January 11, 1999; 112(22): 3985 - 3993. [Abstract] [PDF] |
||||
![]() |
L. T. Duong, I. Nakamura, P. T. Lakkakorpi, L. Lipfert, A. J. Bett, and G. A. Rodan Inhibition of Osteoclast Function by Adenovirus Expressing Antisense Protein-tyrosine Kinase 2 J. Biol. Chem., March 2, 2001; 276(10): 7484 - 7492. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |